Highlights
• Cipla Ltd said its US speciality business division has entered into agreement with US-based SIGA Technologies Inc to develop novel antibiotics
• Cipla Therapeutics has decided to partner with SIGA Technologies in order to develop novel antibiotics, specifically those that target drug-resistant microbials
• At present, Cipla owns and markets the Zemidri injection, a novel antibiotic in t....
Tags : Cipla, Cipla Therapeutics, US news, SIGA Technologies, ,
comments (0)